|
AIDScience Perspectives:
The speed of HIV spread
A study conducted last year by the San Francisco Health Department revealed that approximately 30% of the individuals who recently became HIV positive had used methamphetamine in the last 6 months, adding fuel to the concerned with the association between methamphetamine use and the spread of HIV.
— By Marcia L. Triunfol.
VaxGen: are there hints of race-based effects?
VaxGen has stood by its statement that their AIDSVAX® vaccine holds promise for a mélange of non-white racial subgroups, a conclusion they said was supported by unreleased data correlating protection in these subgroups with higher antibody levels.— By Patricia Kahn, from the IAVI Report.
[About AIDScience articles] [See recent AIDScience articles]
Hot News:
2nd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment (July 13-17, 2003)
Medscape HIV/AIDS is the official provider of online conference coverage and continuing medical education (CME) activities based on the Conference. (Medscape requires one-time free registration)
2nd International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment (July 13-17, 2003)
Kaisernetwork.org, as the official webcaster of the IAS conference, will provide webcasts and other resources for all conference plenary sessions and selected additional sessions.
AIDS vaccines: back to 'plan A'
The received wisdom in AIDS vaccine research is that stimulating cellular immunity is more important than producing antibodies, but some experts are now reviving the antibody strategy. By Erika Check, Nature's Washington biomedical correspondent. Nature 423, 912, 26 June 2003. Free full-text article.
APOBEC3G, a cellular protein that can inhibit HIV during reverse transcription, has been characterized
Three different groups have discovered how APOBEC3G obstructs HIV replication. Its effect can be countered by the HIV-1 virion infectivity factor (Vif). Cell 113, 803, 13 June 2003. See also Nature 424, 94, 3 July 2003, and Nature 424, 99, 3 July 2003.
VaxGen to complete phase III trial in Thailand
Vaccine developer VaxGen Inc. (Nasdaq: VXGN) issued a statement in response to several newspaper articles this week that inaccurately stated that the company was planning to withdraw from its Phase III trial in Thailand.
Progress reported in effort to create a mouse model for HIV
Researchers identified an important role for the splicing inhibitor hp32 in viral replication, which must be considered in the creation of the mouse model for HIV infection. Nature Cell Biology, published online 29 June 2003.
|
